ANTHONY DURNING

Anthony Durning
Principal

Head of CMC Drug Development and consulting services practice. Tony has 25 years of senior management experience in drug development, cGMP manufacturing, and commercialization; including hands-on plant management, budgeting and strategic planning. His experience spans a broad range of small molecule and biologic dosage forms and all aspects of technical and manufacturing operations from active pharmaceutical ingredient (API) through fill and finishing operations for clinical and commercial launch; including: Synercid^®, Abelcet^®, Myocet^®, Taxotere^®, Nasacort^®, Lovenox^®, Thymitaq^®, lixivaptan, and rM-CSF. Anthony has held positions of increasing responsibility at CardioKine Inc, Eximias Pharmaceuticals, Rhone Poulenc Rorer, Bristol Myers Squibb, Aventis, The Liposome Company, Enzo BiochemInc. Tony is an inventor on numerous patents. He received a Bachelors of Science in Biology from Rutgers University in Biology.

//back to bios//